DMRA

Galecto, Inc. NASDAQ Listed Mar 10, 2026

Healthcare ·Medical - Pharmaceuticals ·US · galecto.com

$24.99

Mkt Cap $1.5B

52w Low $2.45 62.8% of range 52w High $38.33

50d MA $25.82 200d MA $17.44

P/E (TTM) -0.2x

EV/EBITDA 1.1x

P/B 0.1x

Debt/Equity 0.0x

ROE -87.3%

P/FCF -4.3x

RSI (14) —

ATR (14) —

Beta 1.60

50d MA $25.82

200d MA $17.44

Avg Volume 302.4K

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

SIC Code

2834

CIK (SEC)

1800315

Phone

781 281 9020

Building 23 · Boston, MA 02453 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 18, 2026	AMC	-0.14	-3.24	-2216.4%	21.15	-0.1%	-9.2%	-14.2%	+9.0%	+13.1%	+18.4%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 24	RBC Capital	Initiates	Outperform	$40	$25.42	$25.85	+1.7%	-2.6%	+0.3%	-4.7%	-5.9%	+0.9%
Feb 17	Guggenheim	Maintains	Buy → Buy	—	$29.12	$30.52	+4.8%	+2.7%	+4.7%	+4.6%	+3.0%	+2.3%
Dec 8	Guggenheim	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—

Data updated apr 25, 2026 5:28am · Source: massive.com